@pesquallie
You are quoting loose and fast with numbers you cannot justify with statistics.
From the PCa commentary
Examples of the relationship of the duration of ADT exposure to subsequent recovery to their
original T levels after stopping ADT are as follows:
- After 3 - 9 months of ADT nearly all men fully recover by about 10 months;
- After 18 - 24 months of ADT only 60% fully recover by about 3 years; and
- After 36 months of ADT exposure only 50% fully recover by ~ 5 years.
It is clear that after receiving ADT for longer than 6-9 months many men never fully return to their
T baseline. This raises the very important question of whether it is safe to offer replacement
testosterone in symptomatic men who have been rendered persistently hypogonadal (<230
ng/dL).
As it shows here whether or not you recover, depends on how long you’ve been on it. Only in the longest cases Do 50% not recover their testosterone. With 3 to 9 months of hormone therapy virtually all of the men return to their previous testosterone levels.
When somebody is first diagnosed with prostate cancer, hormone therapy drops their PSA immediately, and it stops the cells from growing and spread spreading. That is a fact and has been repeated over and over.
Only when somebody becomes castrate resistant does dropping of the hormone therapy help because resistance cells can’t handle testosterone at that point, though not all cells are resistant so some of them would still be suppressed.
You make it sound so simple and it’s actually very complex.
I would like to see your statistics to back up what you were saying.
@jeffmarc
There are many recent studies that show that low testosterone can be a problem. I could not get the web sites to copy properly so you might have to Google the titles to see the articles. Following are a few:
"Testosterone Supplementation After Prostate Cancer Treatment
YouTube - ISSM International Society for Sexual Medicine" - Dr. Mohit Khera (Baylor College of Medicine) and Dr. Gerald Brock (Western U. London) explain the evolving view on testosterone and prostate cancer, noting a shift from seeing testosterone as harmful to recognizing potential therapeutic or preventive roles. Low testosterone is linked to higher risk of high-grade cancer, recurrence, and poorer erectile recovery. 3/28/25
"Testosterone replacement therapy following definitive treatment for prostate cancer: a scoping review of safety and efficacy | International Journal of Impotence Research"
Conclusion: TRT does not increase the advancement of prostate cancer and may actually decrease cancer growth. 11/26/25 summary of 12 studies.
"Testosterone and prostate cancer: What's the connection? - Mayo Clinic"
Conclusion: Studies have shown that testosterone replacement therapy doesn't seem to increase the risk of prostate cancer returning. 10/29/25
"Study Solves Testosterone’s Paradoxical Effects in Prostate Cancer" | Duke Health